DKDaniel Kaschta

Daniel Kaschta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Kaschta has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analytical Performance of the EasyPGX Ready NTRK Fusion Assay for Detecting Tumor-Agnostic NTRK Gene Fusions in Solid Tumors

    by Anna Soiron, Kim Falkenberg, Santina Kirmse, Laura Braun, Elias Dohmen, Daniel Kaschta, Ilka Isfort, Ruth Berthold, Anne Offermann, Eva Wardelmann, et al.

    Early detection and accurate characterization of pathogenic NTRK1, NTRK2, and NTRK3 gene rearrangements have become essential components of multimodal testing frameworks to select gene fusion-positive candidates for NTRK-directed molecularly targeted therapies. This retrospective study presents the first independent validation of the CE-IVD-compliant EasyPGX ready NTRK Fusion assay, a ready-to-use RT-PCR workflow for the qualitative detection of NTRK1,2,3 gene fusions in solid tumors. Based on the fusion frequency in our institutional pathology cohort, the potential diagnostic coverage of the streamlined fast-track assay was 93.8% (15/16) for NTRK1, 100% (1/1) for NTRK2, and 58.8% (10/17) for NTRK3 rearrangement, including TPM3, LMNA, TPR, STRN, and ETV6 as 5′ fusion partners. Twenty-nine archived FFPE tumor specimens with known NTRK1,2,3 gene rearrangement status, and two multiplexed FFPE NTRK fusion reference standards were tested. Targeted RNA-based next-generation sequencing served as the diagnostic benchmark reference method. Conclusive results were obtained for all 31 RNA samples, including FFPE tumor specimens archived for up to six years. The observed overall sensitivity was 96% (23/24; 95% CI, 78.9–99.9%) and no false-positive results were observed for any of the nine gene fusion targets (observed specificity 100%); the single discordant result occurred in a fusion-positive sample with borderline transcript abundance at the lower limit of the assay’s dynamic range. Dilution experiments indicated valid detection at 6.25 ng RNA input per reaction for all fusion transcripts tested, with robust inter-run repeatability and no false-positive results. In this single-center study, the CE-IVD-compliant EasyPGX ready NTRK Fusion assay demonstrated analytical performance within its predefined repertoire of NTRK1,2,3 rearrangements, consistent with guideline thresholds, supporting its potential as a first-level fast-track component of multimodal pan-cancer diagnostic workflows.

  • Open Access

    AUTOMATED VERSUS MANUAL REANALYSIS IN RARE DISEASE GENOMICS

    by Daniel Kaschta, Vincent Arriens, Simon Mueller, Caroline Utermann-Thuesing, Genom- Rd, Inga Vater, Almuth Caliebe, Inga Nagel, Malte Spielmann

    Purpose: Periodic reanalysis of genome sequencing data can yield additional diagnoses as knowledge evolves, yet manual reanalysis is labour-intensive. We compared automated and manual reanalysis approaches in rare disease genomics. Methods: We reanalyzed 377 rare disease cases: 158 with pathogenic or likely pathogenic (P/LP) findings, 49 with variants of uncertain significance (VUS) findings, and 170 had no findings. Manual reanalysis used standard diagnostic workflow for all cases without prior P/LP diagnoses (219 cases). An automated pipeline using Talos was benchmarked on the 158 P/LP cases before application to the 219-case reanalysis cohort. The mean reanalysis interval was 660 days. Results: Manual reanalysis identified three additional P/LP cases and two newly classified as VUS, increasing P/LP cases from 158 (41.9%) to 161 (42.7%). Talos recovered all three P/LP findings but only identified one of the two new VUS findings. Benchmarking showed 80.0% singleton concordance and 75.2% (82.8% proband-only) trio concordance, with an output of approximately three variants per case. Conclusion: Reanalysis at 1.8 years yields modest but clinically meaningful gain. Automated reanalysis closely approximates manual performance while reducing hands-on effort, supporting scalable reanalysis in routine genomic care.